Novartis (NVS) PT Raised to $170 at Morgan Stanley
Tweet
Share
E-mailGet Alerts NVS Hot Sheet
Price: $162.76 +0.18%
Rating Summary:
7 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Rating Summary:
7 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Join SI Premium – FREE
Morgan Stanley analyst Thibault Boutherin raised the price target on Novartis (NYSE: NVS) to $170.00 (from $143.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Novartis MS drug remibrutinib meets Phase III trial goals
- JPMorgan Downgrades Inpex Corp (1605:JP) to Neutral
- Zensho Holdings (7550:JP) PT Raised to JPY13,300 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
